IHMO
LANI can replace TAMIFLU for ROCHE as by then TAMIFLU's patent would have ran out.
I think the success of new products depends on the direction of management of the big PHARMAs. If relenza was pushed by ROCHE in the first place, perhaps Relenza would be sitting much better in the market. If ROCHE makes a deal with BIOTA/SANKYO, it surely will be better than with GSK, at least it does not have GSK's pre-pandemic vaccine to content with for GSK's internal marketing budget.
- Forums
- ASX - By Stock
- BTA
- upgrade from abn amro
upgrade from abn amro, page-6
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online